Mkts

Atrium Therapeutics, Inc.

NASDAQ: RNA
$6.98+0.34 (+5.12%)
As of Nov 19, 4:00 PM ET

Key statistics

Day range
6.657.13
52-week range
6.3673.06
Today
Open6.70
Previous close6.98
Volume533.8K
Valuation
Market cap143.23M
P/E ratio—
EPS (TTM)-5.04
Income & risk
Dividend / yield—
Beta1.26
Avg volume249.2K
Discussion

RNA News

Stories mentioning RNA from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q1 '25Mar 31
Income Statement
Revenue19,6351,573
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development16,6576,937
Sales General & Admin
Total Operating Expenses36,9159,025
Operating Income (Loss)(17,280)(7,452)
Interest Income
Interest Expense
Other Expense
Pretax Income
Tax Provision
Net Income (Loss)(16,633)(7,449)
Earnings Per Share (Basic)(0.97)(0.44)
Earnings Per Share (Diluted)(0.97)(0.44)
Weighted Average Shares Outstanding (Basic)17,10617,106
Weighted Average Shares Outstanding (Diluted)17,10617,106

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About RNA

Atrium Therapeutics, Inc. (NASDAQ: RNA) is a stock listed on the Nasdaq Stock Market under the ticker symbol RNA. It last traded at $6.98 (Nov 19, 2026, 4:00 PM ET), up 5.1% on the day. That gives Atrium Therapeutics a market capitalisation of $143.2M.

Over the past 52 weeks RNA has traded between $6.36 and $73.06.

Revenue for the quarter ended Mar 31, 2026 was $19.6M; a net loss of $16.6M. Revenue was up 1148% from $1.6M in the quarter ended Mar 31, 2025.

Last 2 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$19.6M-$16.6M-84.7%
Mar 31, 2025$1.6M-$7.4M-473.6%

From Atrium Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…